Skip to content

How well and how safely two medicines, Vonoprazan and Pantoprazole, help heal stomach acid damage in the food pipe of patients in a North Indian hospital

Evaluation of efficacy and safety of Vonoprazan in comparison to Pantoprazole in healing of erosive esophagitis in a tertiary care centre in North India: A pilot study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/09/095237
Enrollment
50
Registered
2025-09-22
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K208- Other esophagitis

Interventions

Intervention1: Vonoprazan: Vonoprazan 20mg tablet give once daily orally for duration of 8 weeks. Control Intervention1: Pantoprazole: Pantoprazole 40mg tablet once daily before breakfast for duration

Sponsors

Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: -Patients aged between 18 to 70 years older of either gender. -Treatment naive patients diagnosed with erosive esophagitis on endoscopy. -All grades of erosive esophagitis, L.A. Classification, grade A to D. -Patients or Legally authorised representative willing to provide written informed consent.

Exclusion criteria

Exclusion criteria: -Patients with Helicobacter pylori infection with RUT Kit -Patients with Barret s esophagus. -Patients with chronic kidney disease. -Pregnant or lactating women. -Signs of gastric malignancy on endoscopy. -Suffering from acute infections. -Obese patients with BMI more than 40kg per metre square

Design outcomes

Primary

MeasureTime frame
Healing rate of erosive esophagitisTimepoint: After 8 weeks of treatment

Secondary

MeasureTime frame
Symptom controlTimepoint: Baseline, at 4th & 8th Week;Need for rescue medicationTimepoint: At 4th & 8th Week;Compliance/adherence rate assessed via pill count or patient diary and using Brief Medication Questionnaire (BMQ)Timepoint: At 4th & 8th Week;Improvement in quality of life using GERD-HRQL questionnaire.Timepoint: Baseline, at 4th & 8th Week;Dropouts from the studyTimepoint: At 4th & 8th Week;Safety profile and adverse eventsTimepoint: At 4th & 8th Week (or reported by patient during anytime of the study)

Countries

India

Contacts

Public ContactDr Sumit Kumar

Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences

drsumit.pharma24@gmail.com9991326777

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026